Financials
Financial year 2025
integrated DNA technologies from Leuven, company number BE0473291407, closed financial year 2025 with a result of € 7.7 million after tax. For that financial year integrated DNA technologies recorded revenue of € 57.2 million and equity of € 15.4 million. Compared with financial year 2024, the result moved from € 3.6 million to € 7.7 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2026.
€ 15.4 million
▲ 101% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 7.7 million
▲ 112% vs 2024
Profit after tax over the fiscal year.
€ 7.4 million
▼ 9% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 11.8 million.
People and assets in 2025
175.8
▲ 10.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 20 million
▲ 4% vs 2024
€ 114,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 95,895
▲ € 86,757 vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 6.6 million
▼ 8% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 75 days on average.
€ 2.6 million
▼ 14% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 48,633,625 | € 63,353,035 | € 61,330,342 | € 57,152,038 | ▼ 7% |
| Profit after taxes | € 1,688,038 | € 3,748,683 | € 3,644,673 | € 7,728,517 | ▲ 112% |
| Equity | € 19,278,304 | € 13,026,988 | € 7,671,661 | € 15,400,177 | ▲ 101% |
| Total debts | € 11,264,652 | € 22,887,083 | € 21,931,188 | € 11,986,129 | ▼ 45% |
| Cash | € 10,682,734 | € 12,973,936 | € 8,050,663 | € 7,350,605 | ▼ 9% |
| Retained profit | € 15,640,031 | € 9,388,715 | € 4,033,388 | € 11,761,904 | ▲ 192% |
| Dividend | € 0 | € 10,000,000 | € 9,000,000 | € 0 | ▼ 100% |
| Balance sheet total | € 30,542,957 | € 35,914,071 | € 29,602,849 | € 27,386,307 | ▼ 7% |
| Employees (FTE) | 179.8 | 172.2 | 165.2 | 175.8 | ▲ 10.6 |
Key figures of integrated DNA technologies, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to integrated DNA technologies?
What happened at integrated DNA technologies in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 7.7 million (▲ 112% vs 2024). Source: NBB ↗
- Linda De Jesus stepped down as director. NBB
- Konstantin Fiedler became a director. NBB
- Christine Boge stepped down as director. NBB
- Linda De Jesus became a director. NBB
- Benny Vandecraen became a director. NBB
- Christine Boge became a director. NBB
- New establishment in Leuven. KBO
In short
From € 1.7 million profit in 2022 to € 7.7 million profit in 2025.
Paid € 4.6 million in corporate taxes since 2022.
Best year ever: 2025, with € 7.7 million profit.
Paid out € 19 million in dividends to the owners in total.
A new publication or filing at integrated DNA technologies? We notify you, reason included.
Follow integrated DNA technologiesDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind integrated DNA technologies are Benny Vandecraen and Konstantin Fiedler. The shares are held by Integrated DNA Technologies Inc (100%). It owns 100% of Integrated DNA Technologies UK Ltd, 100% of Integrated DNA Technologies Germany GmbH and 100% of Integrated DNA Technologies Spain SL itself.
Directors
According to the 2025 annual accounts
Benny Vandecraen
Director
since 2016
Konstantin Fiedler
Director
since 2025
Christine Boge
Director
since 2006 · until 2025
Linda De Jesus
Director
since 2023 · until 2025
Shareholders
Integrated DNA Technologies Inc
100%
Participations
Integrated DNA Technologies UK Ltd
100%
Integrated DNA Technologies Spain SL
100%
Establishments
Establishment units
Physical locations of this company
Interleuvenlaan 12A
3001 Leuven
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0473.291.407
- VAT number
- BE 0473.291.407
- Registered office
- Interleuvenlaan 12A, 3001 Leuven
- Names & denominations
- integrated DNA technologies
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 November 2000
- Peppol
- Active · Active since 23 Dec 2025
- Activities · NACE
Vervaardiging van overige organische chemische basisproducten
Vervaardiging van andere organische chemische basisproducten
Vervaardiging van andere chemische producten, neg
Vervaardiging van overige chemische producten